2023 World Conference on Lung Cancer (Posters)-EP17.03. Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy

EP17.03. Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy - PDF(Abstract)

Pdf Summary

This document presents the findings of a study on the patient-reported outcomes (PRO) of treatments for patients with metastatic non-small cell lung cancer (mNSCLC) following progression on or after platinum-based chemotherapy. The study focuses on the use of health state utility values (HSUVs) in health technology assessments (HTAs) conducted in Europe and North America. <br /><br />The researchers conducted an online search of HTA organizations in Europe and North America and identified 17 HTAs with published PRO information on treatments for mNSCLC. The HTAs included assessments of treatments such as nivolumab, pembrolizumab, atezolizumab, and nintedanib/docetaxel. The PRO reported in these HTAs were collected using the EuroQol-5D (EQ-5D) utility data from pivotal trials of the respective treatments.<br /><br />The results show that over 100 utility estimates were used in the 17 HTAs considered. The estimated utilities were based on factors such as time, treatment, programmed death-ligand 1 (PD-L1) status, time-to-death, and disease progression status. The mean and median utility estimates were .662 and .681 respectively, with a range from .284 to .879. The lowest utility estimates were associated with less than 30 days to death, while the highest estimates were associated with over a year from death.<br /><br />The study concludes that while mapping algorithms are available to estimate EQ-5D utility values, there is a higher usage of HSUVs based on EQ-5D data collected from pivotal trials in the HTAs considered. The researchers emphasize the importance of careful deliberation when estimating HSUVs in patients with platinum-resistant mNSCLC, as these values are important input parameters for cost-utility analyses and value assessment of novel treatments.<br /><br />Overall, this study provides insights into the use of HSUVs in HTAs for mNSCLC treatments, highlighting the need for accurate estimation of these values in order to make informed reimbursement decisions.

Asset Subtitle

Cloe Ying Chee Koh

Meta Tag

Speaker Cloe Ying Chee Koh

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

patient-reported outcomes

metastatic non-small cell lung cancer

platinum-based chemotherapy

health state utility values

Europe

North America

nivolumab

pembrolizumab

atezolizumab

nintedanib/docetaxel